Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Leipe

Showing results (81-90 of 83) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 83 results.
Annals of the Rheumatic Diseases|April 25, 2020
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitorsMarie Kostine, Axel Finckh, Clifton O Bingham, et al.
European Journal of Cancer (Oxford, England : 1990)|August 28, 2021
Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuationNoémie Chanson, Manuel Ramos-Casals, Xerxes Pundole, et al.
Seminars in Arthritis and Rheumatism|November 13, 2022
Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica: A scoping review by the OMERACT irAE working groupNilasha Ghosh, Nina Couette, Wouter H van Binsbergen, et al.
Pageof 9

Showing results (81-90 of 83) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 83 results.
Annals of the Rheumatic Diseases|April 25, 2020
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitorsMarie Kostine, Axel Finckh, Clifton O Bingham, et al.
European Journal of Cancer (Oxford, England : 1990)|August 28, 2021
Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuationNoémie Chanson, Manuel Ramos-Casals, Xerxes Pundole, et al.
Seminars in Arthritis and Rheumatism|November 13, 2022
Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica: A scoping review by the OMERACT irAE working groupNilasha Ghosh, Nina Couette, Wouter H van Binsbergen, et al.
Pageof 9